Clay B. Siegall, Ph.D., is a scientist and the man behind Seattle Genetics. Having co-founded it in 1998, he currently serves as the business’ president, CEO, (chief executive officer) and chairman of the board. Siegall’s areas of expertise concerns targeted cancer therapies.
Passionate about helping patients, he co-created Seattle Genetics on the precepts of drug development practices, research, and scientific innovation.
His company leads the way in developing ADCs (antibody-drug conjugates) and in earning FDA (food and drug administration) approval for Adcetris (brentuximab vedotin), their first ADC product, in 2011. He and his company worked with the Takeda Pharmaceutical Company to make Adcetris a worldwide brand that is now greenlighted for use in over 60 countries. They are also working on a number of proprietary ADCs in order to treat cancer.
Doctor Siegall and Seattle Genetics have several specific licenses for their ADC technology as well. They have garnered over $325 million with AbbVie, Genentech (Roche), Pfizer, and GlaxoSmithKline. Thanks to both collaborative and internal efforts, there are presently at least 20 ADCs being clinically developed via the use of Seattle Genetics’ technology. Dr. Siegall is also widely credited for the company’s capital-raising efforts which have brought in over $1.2 billion through private and public financings such as their initial public offering which was launched in 2001.
After he earned his Ph.D. in Genetics from George Washington University, but before the beginnings of Seattle Genetics, Doctor Siegell was employed by Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. He also worked for the National Cancer Institute and National Institutes of Health from 1988 to 1991. Siegall has been honored with a number of different awards such as the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. At present, he sits on the Boards of Directors of Alder BioPharmaceuticals, the Washington Roundtable, and Ultragenyx Pharmaceutical.